Proposed Capital Return to Shareholders of $14.0 Million
Filed with ASX · · 2 pages · English
Invex Therapeutics Ltd. on 6ix
Earlier from Invex Therapeutics
- Invex issued US patent for Traumatic Brain Injury
- Invex to close IIH Evolve Phase III Clinical Trial
- Phase III Clinical Trial Update and New IIH Market Analysis
- Invex Granted European Orphan Drug Designation for TBI
- Invex Receives Regulatory Approval for IIH EVOLVE in France
Later from Invex Therapeutics
- Invex Granted European Patent for Exenatide in Hydrocephalus
- Invex and Peptron Mutually Terminate Manufacturing Agreement
- Appendix 4D and Half year report
- ATO Class Ruling Return of Capital
- Invex receives R&D Tax Rebate
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics